^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERBB3 positive

    i
    Other names: ERBB3, HER3, LCCS2, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
    Entrez ID:
    2065
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    17d
    DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors. (PubMed, J Transl Med)
    These finding demonstrated that DB-1310 exerted potent antitumor activities against HER3 + tumors in in vitro and in vivo models, and showed acceptable safety profiles in nonclinical species. Therefore, DB-1310 may be effective for the clinical treatment of HER3 + solid tumors.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    ERBB3 overexpression • ERBB3 positive
    |
    Tagrisso (osimertinib) • patritumab deruxtecan (U3-1402) • DB-1310
    4ms
    Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements. (PubMed, Diagn Pathol)
    Considering the high cost of NGS, FISH remains a useful method for screening NRG1 fusions in various types of tumors. This study provides valuable insights into the molecular mechanisms of NRG1 fusion and identifies potential treatment targets for patients suffering from this disease.
    Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)
    |
    ERBB3 expression • NRG1 fusion • ERBB3 positive • NRG1 rearrangement • NRG1 fusion
    5ms
    U31402-A-J101: Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=184, Completed, Daiichi Sankyo Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Sep 2023
    Trial completion • Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HR positive • HER-2 negative • HER-2 expression • ERBB3 positive
    |
    patritumab deruxtecan (U3-1402)
    10ms
    A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours (ESMO 2023)
    HMBD-001 will next be evaluated in Part B in biomarker selected mCRPC with Enzalutamide. Trials of HMBD-001 in squamous NSCLC and NRG1 fusions are also planned for Q3/4 2023.
    Clinical • P1/2 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NRG1 (Neuregulin 1)
    |
    NRG1 fusion • ERBB3 overexpression • ERBB3 positive • NRG1 fusion
    |
    Xtandi (enzalutamide capsule) • HMBD-001
    10ms
    U31402-A-J101: Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=184, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HR positive • HER-2 negative • HER-2 expression • ERBB3 positive
    |
    patritumab deruxtecan (U3-1402)